Quantum-Si incorporated (QSI) Company Overview

What does Quantum-Si do?

Quantum-Si Incorporated is a Nasdaq-listed life-sciences tools company developing benchtop systems for next-generation protein sequencing. Its central idea is that researchers should be able to read proteins directly at the single-molecule level rather than infer biology only from DNA, RNA, antibodies, or conventional mass spectrometry. The company’s 2025 Form 10-K describes a platform built around semiconductor-enabled detection, sequencing chemistry, sample preparation, instruments, and analysis software.

What products define the current platform?

The commercial portfolio includes Platinum and Platinum Pro instruments, library-preparation kits, barcoding kits, sequencing kits, and Platinum Analysis Software. Platinum was positioned near an $85,000 price point, while Platinum Pro was priced near $120,000 in the 2025 annual filing. The consumable used with the current system contains roughly two million features. Platinum Pro added a redesigned interface, cloud or on-instrument analysis, and a “Pro Mode” for customers developing custom methods.

Why does protein sequencing matter?

Proteins are the functional machinery of cells, and their variants, isoforms, and post-translational modifications can carry information that genomic sequencing alone does not reveal. Quantum-Si is trying to make amino-acid-level analysis easier to run in ordinary laboratories. The opportunity is meaningful, but the company remains at an early commercialization stage: current revenue is tiny relative to operating spending, and the investment case is driven more by technical adoption and platform scaling than by established earnings.

How does Quantum-Si make money?

Quantum-Si uses a classic life-sciences tools model: sell instruments, then generate recurring revenue from proprietary consumables, software access, maintenance, and training. Product revenue includes instruments, sequencing kits, library-preparation kits, and freight. Service revenue includes maintenance contracts, software access, and advanced training. The long-term economic goal is an expanding installed base that repeatedly purchases consumables.

Which revenue source matters most today?

What is the core economic tension?

The model is attractive only if instrument placements lead to sustained consumable pull-through. In FY2025, product revenue was $2.286 million and service revenue was $150,000. That mix shows that Quantum-Si has not yet reached a recurring-revenue flywheel. Near-term customers may also defer Platinum Pro purchases while waiting for Proteus, creating a transition gap before the next platform is commercially available.

What does the latest quarter show?

The quarter ended March 31, 2026 shows a company deliberately spending through a product transition. According to the Q1 2026 Form 10-Q, revenue fell 69.4% year over year to $258,000 as customers delayed instrument and consumable decisions ahead of Proteus. Gross profit was $74,000 and gross margin fell to 28.7%, versus 57.7% in Q1 2025.

Where did spending go?

Research and development expense rose 5.6% to $14.487 million, driven by laboratory supplies, payroll, fabrication, and outsourced services supporting Proteus. Selling, general and administrative expense declined 18.9% to $9.640 million, partly because legal, payroll, marketing, and consulting costs were lower. Total operating expenses were $24.127 million, down 5.7%, yet the revenue base was far too small to absorb that cost structure.

Why did revenue fall before a major launch?

Management explicitly linked the decline to customers deferring purchases while waiting for Proteus. This is an example of product-transition cannibalization: the future platform may improve the strategic story while weakening current-period sales. The Q1 2026 earnings release emphasized successful sequencing on integrated Proteus instruments and the sequencing of initial customer samples on a prototype, but commercial evidence remains ahead rather than behind the company.

Proteus is the strategic hinge

Proteus is intended to move Quantum-Si from a low-throughput first-generation platform toward a more scalable system with broader applications. The first version is designed around an approximately 80-million-feature chip, compared with two million features in the current Platinum Pro consumable. That implies a 40-fold increase in feature count, although feature count alone does not guarantee commercially useful throughput, accuracy, workflow reliability, or customer adoption.

What capabilities is Proteus supposed to add?

The company announced a $425,000 list price for Proteus in its full-year 2025 earnings release. That higher price signals a move toward core laboratories and institutions able to justify larger capital purchases. It also raises the adoption hurdle: customers will expect a meaningful increase in throughput, reproducibility, supported applications, and total workflow value.

Which milestones matter before launch?

• Integrated instrument performance must translate from internal runs to customer samples.
• Consumable manufacturing must deliver reliable chips and chemistry at acceptable yields.
• Library preparation must remain simple, with the version 3 kit requiring 200 nanograms or less of protein input.
• Applications and analysis software must produce decision-useful outputs, not merely raw sequencing events.
• Commercial readiness must include service, training, inventory, and sales-channel support.

How did Quantum-Si reach this point?

The company was founded in 2013 and became publicly traded through a 2021 business combination. Its history is best understood as a sequence of technical de-risking and commercialization steps rather than as a conventional revenue-growth story.

1. 2013
   Legacy Quantum-Si was founded to pursue semiconductor-based single-molecule detection for protein analysis.
2. 2021
   The company completed its business combination and began trading on Nasdaq, providing substantial capital for development and commercialization.
3. 2022
   A controlled research-use-only launch of Platinum began, moving the platform from development into early customer workflows.
4. 2023
   Controlled commercial launch expanded the installed base and generated initial instrument and consumable revenue.
5. 2024
   Full commercial launch of Platinum and announcement of the Proteus roadmap shifted attention toward scale and throughput.
6. 2025
   Platinum Pro shipped, the version 3 library-preparation kit improved input requirements by 100-fold, and Proteus prototype milestones advanced.
7. 2026
   Management targets a year-end Proteus launch while current-platform revenue is pressured by customer deferrals.

What did the public listing change?

The 2021 transaction brought roughly $511 million of proceeds at closing, allowing Quantum-Si to fund several years of R&D before meaningful commercial scale. The consequence is a balance sheet that has historically carried large cash and investment balances, but also a cost structure built for development rather than current revenue. Investors therefore assess the company less like a profitable tools vendor and more like a platform with finite runway and milestone risk.

What gives Quantum-Si a competitive advantage?

Quantum-Si’s potential moat rests on integration. Its system combines semiconductor chips, sequencing chemistry, sample preparation, single-molecule kinetic detection, analysis software, and accumulated protein-sequencing data. A competitor would need to reproduce several layers of the workflow, not just build an instrument. The company also claims first-to-market status in commercially available next-generation protein sequencing with Platinum and Platinum Pro.

Where could switching costs emerge?

Switching costs would come from validated protocols, trained staff, accumulated datasets, custom methods, software workflows, and published research built on the platform. However, those advantages only become durable after a sufficiently large community uses the instruments. Today, the company has intellectual property and know-how, but it does not yet have the broad installed base, service network, or purchasing power of large life-sciences tools companies.

What limits the moat today?

Large competitors can spend more on R&D, manufacturing, sales, and support. Customers can also continue using mass spectrometry or affinity-based proteomics, which already have established workflows and extensive scientific validation. Quantum-Si must therefore prove not merely that its technology works, but that it solves enough important problems to justify new capital equipment and recurring consumable spending.

Who are Quantum-Si’s main competitors?

The 2025 annual report names both established tools companies and emerging proteomics developers. Large competitors include Agilent Technologies, Bio-Rad Laboratories, Danaher, Merck KGaA and MilliporeSigma, and Thermo Fisher Scientific. Emerging competitors include Nautilus Biotechnology, Quanterix, Seer, and technologies associated with Olink and SomaLogic. The competitive set is broader than direct NGPS rivals because laboratories allocate budgets across mass spectrometry, affinity assays, sequencing, imaging, and outsourced services.

What determines market position?

The decisive factors will be accuracy, proteome coverage, reproducibility, sample input, throughput, total cost per useful result, workflow simplicity, service quality, and the number of high-value applications supported. A technically novel platform can still lose if it is harder to validate or integrate than incumbent methods. Conversely, even a modest initial instrument base could become strategically important if published customer data shows unique biological insight.

How financially strong is Quantum-Si?

Quantum-Si has substantial liquidity but also substantial cash consumption. At March 31, 2026, cash and cash equivalents were $36.2 million, current marketable securities were $91.1 million, and total cash plus current and non-current marketable securities were $190.4 million. Net cash used in operating activities was $25.6 million in Q1 2026. At that quarterly pace, liquidity can decline quickly, although spending and working capital are not perfectly even across quarters.

What does the annual financial profile show?

How should cash runway be interpreted?

Management said at year-end 2025 that $215.8 million could support operations into the second quarter of 2028. That outlook depended on planned spending, modest inventory build, and execution around Proteus. The balance had already declined by $25.4 million by March 31, 2026. Researchers should monitor both absolute cash use and the reasons for it: spending that produces a launch-ready platform is very different from spending caused by delays, low manufacturing yields, or weak demand.

Who owns Quantum-Si stock, and why does control matter?

Quantum-Si has a dual-class structure. As of March 20, 2026, there were 196.4 million Class A shares and 19.9 million Class B shares outstanding. Class A carries one vote per share, while Class B carries 20 votes per share. The 2026 proxy statement shows that founder and chairman Jonathan Rothberg beneficially controlled all Class B shares and approximately 69.33% of total voting power.

What are the governance implications?

The structure supports long-duration product development because management is less exposed to short-term voting pressure. The trade-off is weaker outside-shareholder influence over strategy, board composition, compensation, and capital allocation. For a pre-profit company, that matters: future equity issuance may dilute economic ownership, yet voting control can remain concentrated because of the super-voting Class B shares.

What opportunities and risks could change the story?

The upside case is straightforward: Proteus launches on time, delivers materially higher throughput, wins reference laboratories, and creates recurring consumable demand. The risk case is equally clear: launch slippage, weaker-than-expected performance, customer hesitation, or a faster competitive platform could consume runway before the business reaches scale.

Which risks are most material?

The annual report’s risk discussion highlights commercialization uncertainty, dependence on technical milestones, limited revenue history, competition from better-resourced companies, intellectual-property challenges, supplier and manufacturing dependence, regulation, cybersecurity, personnel retention, and future financing needs. Proteus creates concentration risk because it is expected to carry much of the next growth phase.

What opportunities could create operating leverage?

A successful launch could improve the economics in several ways: higher instrument pricing, broader sample throughput, more consumables per installed system, a larger application menu, software-enabled retention, and distribution leverage. Quantum-Si also has international exposure: FY2025 international revenue was $1.737 million versus $699,000 domestically, showing that adoption is not limited to the United States. Still, the absolute figures are too small to establish a durable geographic advantage.

Why does Quantum-Si matter for valuation?

A conventional earnings multiple is not especially informative because Quantum-Si has minimal revenue and large operating losses. A DCF must instead be built from adoption assumptions: instrument placements, average selling price, utilization, consumable revenue per instrument, service revenue, gross margin at scale, operating expense growth, and future financing. The terminal value will be highly sensitive to whether the platform becomes a category standard or remains a niche research tool.

For comparable-company analysis, mature life-sciences tools firms offer useful margin and recurring-revenue benchmarks, while pre-commercial proteomics companies provide risk-stage context. Neither comparison is perfect. Quantum-Si’s valuation will likely move most sharply with technical milestones, customer evidence, and cash runway rather than with small changes in quarterly revenue.

What is the key takeaway from Quantum-Si analysis?